Stryker Corporation $SYK Shares Acquired by Capital Investment Services of America Inc.

Capital Investment Services of America Inc. increased its holdings in shares of Stryker Corporation (NYSE:SYK) by 0.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,795 shares of the medical technology company’s stock after buying an additional 111 shares during the quarter. Stryker accounts for about 2.8% of Capital Investment Services of America Inc.’s portfolio, making the stock its 13th largest position. Capital Investment Services of America Inc.’s holdings in Stryker were worth $30,382,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. GAMMA Investing LLC grew its position in Stryker by 16.4% during the 1st quarter. GAMMA Investing LLC now owns 5,574 shares of the medical technology company’s stock worth $2,075,000 after purchasing an additional 785 shares during the period. Continuum Advisory LLC raised its stake in shares of Stryker by 5.8% during the 1st quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company’s stock valued at $198,000 after buying an additional 29 shares during the last quarter. Consolidated Portfolio Review Corp acquired a new position in shares of Stryker in the 1st quarter valued at about $231,000. Finally, Cornerstone Wealth Group LLC boosted its stake in shares of Stryker by 4.1% in the first quarter. Cornerstone Wealth Group LLC now owns 2,114 shares of the medical technology company’s stock worth $787,000 after buying an additional 83 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Up 2.1%

Shares of NYSE SYK opened at $387.84 on Thursday. The stock has a market cap of $148.27 billion, a PE ratio of 51.37, a P/E/G ratio of 2.74 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The company has a 50-day moving average of $379.74 and a 200 day moving average of $379.16.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. During the same period last year, the company earned $2.81 EPS. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is 44.50%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. BTIG Research boosted their price target on Stryker from $407.00 to $408.00 and gave the company a “buy” rating in a report on Monday, October 13th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Evercore ISI dropped their target price on Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Wells Fargo & Company lifted their price target on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Finally, Rothschild & Co Redburn initiated coverage on Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target on the stock. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $432.24.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.